Hydrocodone/paracetamol - Acura Pharmaceuticals

Drug Profile

Hydrocodone/paracetamol - Acura Pharmaceuticals

Alternative Names: Acetaminophen/hydrocodone; Acetaminophen/hydrocodone bitartrate; Aversion H&A; Hydrocodone bitartrate/acetaminophen; Hydrocodone bitartrate/APAP tablets; Hydrocodone bitartrate/paracetamol; Hydrocodone/acetaminophen; LTX 03; Paracetamol/hydrocodone; Paracetamol/hydrocodone bitartrate; Vycavert Tablets

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Acura Pharmaceuticals
  • Class Acetanilides; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 01 Mar 2016 Acura Pharmaceuticals initiates formulation development of Limitx™-based hydrocodone/paracetamol for Pain in USA (PO)
  • 04 May 2015 Acura Pharamceuticals suspends the development of Aversion®-based formulation (Acura Pharmaceuticals 10-Q, May 2015)
  • 09 Apr 2015 Early research of Limitx™-based formulation in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top